Hong Kong & China Medical Device Regulatory Outsourcing

Mandatory in-country testing, the necessity for local legal representation, and the frequent updates to regulations and technical standards contribute to a highly intricate approval process. These requirements differ significantly from those in the U.S. or EU, making local expertise and assistance not just beneficial, but essential.

For medical device companies, this complexity emphasizes three critical priorities: accelerating time to market, ensuring full regulatory compliance, and controlling operational costs. Achieving all three internally is challenging, especially without a dedicated team on the ground in China. This is why outsourcing regulatory affairs to a specialist provider offers a strategic advantage.

Cisema assists international medical device companies with comprehensive regulatory affairs and compliance services specifically tailored to China. We help you register, launch, and maintain your products in full compliance with NMPA requirements, without the need to develop internal capabilities in China.

We function as your external regulatory department, managing every step from marketing authorizations to PMS. This allows you to stay compliant, competitive, and focused on your core business.

GMP Medical Devices
Outsourcing service

Benefits of Regulatory Affairs Outsourcing Services for China

Local Expertise with Global Integration

Cisema experts will guide you at every stage of product development, ensuring compliance, strategic alignment and a successful market entry. We facilitate interactions with regulatory agencies to streamline the approval process.  

Accelerated Access

By outsourcing regulatory tasks, companies can expedite approvals, seizing commercial opportunities more quickly and responding swiftly to demand.

Efficient

Eliminating the need for internal teams to manage complex regulations reduces overhead and enhances financial efficiency.

Concentration on Core Strengths

By delegating regulatory responsibilities, your internal teams can focus on innovation, production, and business growth, thereby boosting productivity.

Access to Specialized Knowledge

Partnering with an experienced regulatory outsourcing firm like Cisema grants you access to advanced regulatory strategies and technical expertise for efficient authorizations.

Enhanced Compliance & Risk Management

We assist in establishing robust quality systems, maintaining precise documentation, conducting audits, and ensuring adherence to NMPA standards — minimizing the risk of non-compliance.

Independent & Confidential Service

We operate solely on your behalf. As we are not a distributor, there is no conflict of interest, ensuring transparency and trust.

Our Regulatory Affairs Outsourcing Services

Our global presence, including offices in Europe, North America and Asia, allows us to provide a wide range of outsourcing services to medical device companies internationally. We understand the importance of regulatory compliance and quality management systems (QMS) for companies.

NMPA Approvals

Class I, II, and III medical devices
Local type testing, clinical evaluation, and dossier submission
Fast-track and innovative device pathways

Legal Agent & In-Country Representative

Act as your local agent with the NMPA
Maintain product licenses and regulatory compliance
Liaise with Chinese authorities on your behalf

Post-Market Surveillance

Adverse event reporting assistance
Change notifications and license renewals
UDI and tracking system support

Quality Management & Compliance

Compliance with Chinese GMP
Internal audits and documentation support
Risk management planning and implementation

Labeling & Packaging Compliance

Chinese Label and IFU review
UDI and barcode checks
Language and format verification

Regulatory Documentation & Control

Document control and quality system maintenance
Accurate, up-to-date documentation aligned with NMPA expectations

Training & Consultancy

Risk management and quality system training
Preparation for on-site inspections and supplier audits

Useful Articles

View More

How China IVD Risk Classification Determines Your NMPA Registration Pathway

Learn how China IVD risk classification works under NMPA rules and see common compliance pitfalls to avoid.

July 13, 2026
How China IVD Risk Classification Determines Your NMPA Registration Pathway

A Guide to South Korea Medical Device Regulation for Global Manufacturers

Understand South Korea’s medical device regulations, from classification to approval and post-market compliance.

July 10, 2026
A Guide to South Korea Medical Device Regulation for Global Manufacturers

Understanding South Korea's Strategic Roadmap for Digital Medical Product Safety Management

Learn how MFDS’s Digital Medical Product Safety Management Roadmap will shape future compliance requirements for digital medical products in Korea.

July 10, 2026
Understanding South Korea's Strategic Roadmap for Digital Medical Product Safety Management
Stock photo of a Korean man in his early 30s sitting comfortably in a bright, contemporary apartment in South Korea, casually reviewing a health monitoring app on his smartphone while wearing a small continuous glucose monitor (CGM) sensor on his arm.

What Is the MFDS? Understanding South Korea’s Medical Device Authority

Learn how South Korea’s Ministry of Food and Drug Safety regulates medical devices, including classification, application review and post-market duties.

July 10, 2026
What Is the MFDS? Understanding South Korea’s Medical Device Authority

Explained: South Korea Medical Device Classification (Class I, II, III, & IV)

Learn how South Korea medical device classification works under the MFDS.

July 10, 2026
Explained: South Korea Medical Device Classification (Class I, II, III, & IV)
Stock photo of an adult South Korean patient wearing a continuous glucose monitor (CGM) on the upper arm during a routine appointment in a modern hospital outpatient clinic

China NMPA Fee Catalogue for Drugs & Medical Devices

Learn the latest China NMPA registration fees for imported and domestic drugs and medical devices.

July 10, 2026
China NMPA Fee Catalogue for Drugs & Medical Devices
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and 
outsourcing solutions to help your business thrive.

China Medical Device Approvals

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Latest Insights

View More

China Expands MRI Registration Requirements Under New 2026 Review Guideline

Manufacturers seeking MRI registration in China must meet expanded technical, software, and validation requirements.

July 16, 2026
China Expands MRI Registration Requirements Under New 2026 Review Guideline
Chinese male MRI technician in a clinical, sterile medical imaging room. The man has a warm, focused expression and is wearing a dark blue medical-style t-shirt

China Releases First Regulatory Guidance for Brain-Computer Interface Medical Devices

China's new BCI medical device guidance establishes classification and naming principles, giving manufacturers a clearer pathway to NMPA registration.

July 14, 2026
China Releases First Regulatory Guidance for Brain-Computer Interface Medical Devices

Hainan MPA Issues Trial Lecheng Real-World Data Guideline for Imported Drug & Medical Device Registration

New Hainan MPA guidance clarifies how Lecheng real-world evidence can support imported product registration, labeling updates, and post-approval activities

July 2, 2026
Hainan MPA Issues Trial Lecheng Real-World Data Guideline for Imported Drug & Medical Device Registration
A clinical trial in Hainan, China, inside a clinical research consultation room at a  hospital. A Chinese doctor in a white lab coat seated across from an adult study participant discussing routine trial procedures, a second researcher reviewing data.

Malaysia MDA Fully Adopts Electronic Establishment Licenses in 2026

MDA will issue only electronic establishment licenses, affecting medical device manufacturers, importers, and distributors.

June 11, 2026
Malaysia MDA Fully Adopts Electronic Establishment Licenses in 2026
stock photograph of a patient and healthcare professional in a modern Malaysian hospital cardiology department

Indonesia Removes IDAK Renewals Under New Licensing Framework

Indonesia removes IDAK renewals, mandates SDAK and IPAK transitions, and shortens correction timelines under risk-based licensing.

June 11, 2026
Indonesia Removes IDAK Renewals Under New Licensing Framework

Malaysia MDA Publishes First Edition Guidance on Change Management for Registered Medical Devices

New MDA guidance introduces a risk-based framework for managing post-registration medical device changes, including software updates and SaMD.

June 11, 2026
Malaysia MDA Publishes First Edition Guidance on Change Management for Registered Medical Devices
stock photo of an advanced handheld vein visualization device being used by a Malaysian nurse in a modern private hospital treatment room in Malaysia
Previous
Previous

A Reliable Partner from Start to Finish

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global medtech leaders alike to manage China regulatory affairs with efficiency and precision. Contact us today to discuss how we can support your China strategy.

Request Proposal